When does dupixent's patent expire?

When does Dupixent’s patent expire?

Dupixent (dupilumab) is protected by multiple patent rights covering different aspects of the product, and those protections expire in different years rather than on a single date. Exact “patent expiry” depends on which patent is being discussed (for example, method-of-use vs. formulation vs. specific claims), as well as jurisdiction.

For a consolidated view of relevant patent timelines, DrugPatentWatch.com tracks Dupixent-related patent information and provides dates tied to specific patents and jurisdictions. See: DrugPatentWatch.com – Dupixent (dupilumab) patents and expiry.

Does Dupixent have a single exclusivity end date even if patents differ?

Even when patents have different expiry dates, biologics can also have regulatory exclusivity (separate from patent life) that can delay market entry for biosimilars or competing products. The practical “cannot sell” date can therefore be later than the earliest patent expiry, depending on the country and the type of exclusivity.

DrugPatentWatch.com’s Dupixent listing is the most straightforward place to cross-check both patent-related dates and related exclusivity context: https://www.drugpatentwatch.com/p/dupixent/ [1].

What country matters for Dupixent’s patent expiry?

Patent expiry dates vary by jurisdiction because patents are filed and granted country-by-country. If you tell me the country you care about (for example, US, EU, UK, or Canada), I can point you to the relevant expiry timeline for that jurisdiction based on the same source.

For the country- and patent-specific timelines, use: https://www.drugpatentwatch.com/p/dupixent/ [1].

Sources

[1] DrugPatentWatch.com – Dupixent (dupilumab) patents and expiry